Brokerage Firm Rating Update on Immunomedics (IMMU)

Immunomedics (IMMU) : Zacks Investment Research ranks Immunomedics (IMMU) as 5, which is a Strong Sell recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 2 research analysts is 2, which indicates as a Buy.


For the current week, the company shares have a recommendation consensus of Buy. Also, Equity analysts at the Brokerage firm Wells Fargo downgrades its rating on Immunomedics (NASDAQ:IMMU). The rating major has initiated the coverage with market perform rating on the shares. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on June 21, 2016.

Immunomedics (NASDAQ:IMMU): The stock opened at $2.81 and touched an intraday high of $2.91 on Wednesday. During the day, the stock corrected to an intraday low of $2.77, however, the bulls stepped in and pushed the price higher to close in the green at $2.86 with a gain of 1.06% for the day. The total traded volume for the day was 501,882. The stock had closed at $2.83 in the previous trading session.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Companys technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Its product candidates include 90Y-clivatuzumab tetraxetan. Its radiolabeled antibody is in a Phase III registration trial in patients with advanced pancreatic cancer. Its portfolio of investigational products also includes antibody-drug conjugates (ADCs). Its ADCs consist of sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. It has other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in clinical and pre-clinical development-stages.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.